Daiichi Sankyo reorganizes US commercial operations to support upcoming specialty pipeline

Japanese drug major Daiichi Sankyo (TYO: 4568) has said it will reorganize its US commercial organization as it begins to transition from a maturing primary care product portfolio to a differentiated specialty portfolio that will include areas such as cardiovascular, pain management and oncology.

"As we face the loss of exclusivity in the coming year of our largest product, we also look ahead to great opportunities with our emerging portfolio in cardiology, oncology, fibromyalgia and pain relief," said Ken Keller, president, US Commercial, at Daiichi Sankyo Inc, adding: "This calls for us to restructure our organization into a smaller, highly-targeted and efficient operating model, with a greater emphasis on customer-facing roles.

Decision comes after already and looming patent expiries